adenine has been researched along with naphthalimides in 114 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (13.16) | 18.7374 |
| 1990's | 52 (45.61) | 18.2507 |
| 2000's | 20 (17.54) | 29.6817 |
| 2010's | 25 (21.93) | 24.3611 |
| 2020's | 2 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Camacho Sánchez, MA; Torres Suárez, AI | 1 |
| Alberts, DE; Gallion, HH; Hynes, HE; Liu, PY; Mills, G; O'Sullivan, J; O'Toole, RV; Smith, HO | 1 |
| Comis, RL; Nash, SL; O'Dwyer, PJ; Ozols, RF; Perez, RP | 1 |
| Alberts, DS; Craig, JB; Hannigan, EV; Liu, PY; Malviya, VK; Surwit, EA | 1 |
| Bonnet, JD; Braun, TJ; Crowley, J; Hanson, KH; Keppen, M; Salmon, SE | 1 |
| Abbruzzese, JL; Ajani, JA; Bradof, JE; Daugherty, K; Levin, B; Linke, K; Pazdur, R; Winn, R | 1 |
| Craig, JB; Crawford, ED; Goodman, P; Higano, CS; Kish, JA; Rivkin, SE; Wolf, M | 1 |
| Depisch, D; Dittrich, C; Gisslinger, H; Haider, K; Kornek, G; Linkesch, W; Scheithauer, W | 1 |
| Berger, MZ; Dimaggio, JJ; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD; Potanovich, LM | 1 |
| Berezin, F; Janisch, L; Mick, R; Ratain, MJ; Schilsky, RL; Smiddy, J; Williams, SF | 1 |
| Diasio, RB; Stagg, MP | 1 |
| Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S | 1 |
| Comis, RL; Hudes, GR; O'Dwyer, PJ; Ozols, RF; Paul, AR; Walczak, J | 1 |
| Depisch, D; Haider, K; Kornek, G; Scheithauer, W | 1 |
| Ayoub, J; Cormier, Y; Eisenhauer, EA; Evans, WK; Laberge, F; Shepherd, FA; Wierzbicki, R | 1 |
| Arteaga, CL; Brown, TD; Craig, JB; Harman, GS; Havlin, KA; Koeller, JM; Kuhn, JG; Von Hoff, DD; Weiss, GR | 1 |
| Craig, JB; Hardy, J; Harman, G; Havlin, K; Koeller, J; Kuhn, JG; Melink, TJ; Phillips, J; Saez, R; Weiss, GR | 1 |
| Hsiang, YH; Jiang, JB; Liu, LF | 1 |
| Lemmer, B | 1 |
| Feun, LG; Hsu, TC; Liang, J; Lu, K; Savaraj, N | 1 |
| Andersson, BS; Bakic, M; Beran, M; Newman, RA; Silberman, LE; Zwelling, LA | 1 |
| Ajani, JA; Baker, FL; Spitzer, G | 1 |
| Lu, K; McLean, MA; Newman, RA; Vestal, ML | 1 |
| Malspeis, L; Ratain, MJ; Schilsky, RL; Staubus, AE | 1 |
| Felder, TB; Krakoff, IH; Legha, SS; Newman, RA; Raber, M; Ring, S | 1 |
| Kroschel, DM; Moore, DJ; Powis, G | 1 |
| Lu, K; Newman, RA; Savaraj, N | 1 |
| Braña, MF; García Gancedo, A; Gil-Fernández, C; Paez, E; Pérez, S; Rodriguez, F; Roldán, CM; Vilas, P | 1 |
| Braña, MF; Garcá Gancedo, A; Gil-Fernández, C; Paez, E; Perez, S; Rodriguez, F; Roldán, CM; Vilas, P | 1 |
| Braña, MF; Cañete, M; Stockert, JC | 1 |
| Buckner, JC; Burch, PA; Cascino, TL; Gallagher, JG; Goldberg, RM; Levitt, R; Morton, RF; O'Fallon, JR; Scheithauer, BW; Westberg, MW | 1 |
| Alberts, DS; Dorr, RT; Remers, WA; Sami, SM; Sólyom, AM | 2 |
| Burris, HA; Eckardt, JR; Fields, S; O'Rourke, T; Rodriguez, GI; Rothenberg, ML; Weiss, GR | 1 |
| Capranico, G; De Isabella, P; Zunino, F | 1 |
| Allen, SL; Costanza, M; Henderson, IC; Ratain, MJ; Rosner, G; Schilsky, RL; Van Echo, DA | 1 |
| Bauman, A; Benson, AB; Blough, RR; Carroll, RB; French, SL; Kilton, LJ; Mullane, MR; Schilsky, RL; Wade, JL | 1 |
| Ahmann, F; Blumenstein, B; Craig, JB; Crawford, ED; Eisenberger, M; Marshall, ME; Thompson, IM | 1 |
| Camacho, MA; Gil, ME; Obregón, MM; Ruz, V; Torres, AI | 1 |
| Balcerzak, SP; Buys, SS; Metch, B; Neefe, JR; Stuckey, WJ | 1 |
| Mick, R; Ratain, MJ | 1 |
| Asbury, RF; Blessing, JA; Soper, JT | 1 |
| Burch, PA; Kovach, JS; Marschke, RF; O'Connell, MJ; Rubin, J; Schutt, AJ; Wieand, HS | 1 |
| Depisch, D; Dittrich, C; Fazeny, B; Haider, K; Kornek, G; Raderer, M; Scheithauer, W | 1 |
| Bousquet, P; Braña, MF; Castellano, JM; Emling, F; Keilhauer, G; Morán, M; Pérez de Vega, MJ; Qian, XD; Romerdahl, CR; Schlick, E | 1 |
| Asbury, RF; Blessing, JA; Clarke-Pearson, D; Homesley, HD; Look, KY | 1 |
| Alberts, DS; Craig, JB; Liu, PY; Malviya, VK; O'Sullivan, J; O'Toole, R; Rosenoff, S; Surwit, E; Ward, JH; Yu, A | 1 |
| Conrad, ME; Eisenberg, P; Fisher, RI; Fleming, T; MacDonald, JS; Poplin, E | 1 |
| Benvenuto, JA; Johnston, DA; Nishioka, K | 1 |
| Ebbert, LP; Foley, JF; Gesme, DH; Hatfield, AK; Jett, JR; Krook, JE; Mailliard, JA; Maksymiuk, AW; Schreffler, DD; Su, JQ | 1 |
| Brown, TD; Craig, JB; Einstein, AB; Fleming, T; Goodman, PJ; Macdonald, JS | 1 |
| Berezin, F; Janisch, L; Lane, LB; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Braña, MF; Castellano, JM; Emling, F; Klebe, G; Kluge, M; Morán, M; Schlick, E; Walker, N | 1 |
| Blum, R; Bonomi, P; Chang, AY; Smith, JL; Smith, TJ; Tu, ZN; Wiernik, PH | 1 |
| Akerman, S; Allen, SL; Budman, DR; Calabro, A; Chan, K; Fusco, D; Hock, K; Kreis, W; Mittelman, A; Puccio, C; Spigelman, M | 1 |
| Benson, AB; Blough, R; French, S; Kies, M; Kilton, LJ; Lad, T; Mullane, M; Rosen, F; Vokes, EE; Wade, J | 1 |
| Bear, S; Remers, WA | 1 |
| Berezin, F; Janisch, L; Kut, M; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Kennedy, MJ | 1 |
| Elson, P; Hsieh, P; Oken, MM; Trump, DL; Witte, RS | 1 |
| Adams, GL; Dutcher, JP; Leaf, AN; Neuberg, D; Ritch, PS; Schwartz, EL; Wadler, S | 1 |
| Asbury, R; Blessing, JA; Buller, R; Look, KY; Lucci, JA | 1 |
| Gale, KC; Hsiung, Y; Nitiss, JL; Osheroff, N; Rose, A; Zhou, J | 1 |
| Asbury, R; Blessing, JA; Buller, R; Malfetano, JH; Sevin, BU; Walker, J | 1 |
| Asbury, R; Ball, H; Blessing, JA; Podczaski, E | 1 |
| Asbury, R; Blessing, JA; McGuire, WP; Reid, GC | 1 |
| Berkowitz, I; Berry, D; Costanza, ME; Duggan, D; Henderson, IC; Kalra, J; Lyss, AP; Ratain, MJ; Shapiro, C; Wu, K | 1 |
| Berry, DA; Cirrincione, C; Costanza, ME; Frei, E; Henderson, IC; McIntyre, OR; Norton, L; Schilsky, RL; Weiss, RB; Winer, E; Wood, WC | 1 |
| Innocenti, F; Iyer, L; Ratain, MJ | 2 |
| Alberts, DS; Dorr, RT; Hersh, EM; Liddil, JD; Remers, W; Sami, SM | 1 |
| Brown, TD; Craig, JB; Jaeckle, K; Rankin, C; Solank, DL; Taylor, SA; Townsend, JJ; Vance, RB | 1 |
| Abradelo, C; Báñez-Coronel, M; Braña, MF; Cacho, M; de Pascual-Teresa, B; Domínguez, MT; García, MA; Lacal, JC; Pozuelo, JM; Ramos, A; Rey-Stolle, MF; Yuste, M | 1 |
| Bernabeu, JA; Camacho, MA; Gil-Alegre, ME; Torres-Suarez, AI | 1 |
| Li, Z; Qian, X; Yang, Q | 1 |
| Acevedo, O; Jorgensen, WL | 1 |
| Fujitsuka, M; Kawai, K; Majima, T; Osakada, Y | 2 |
| Cai, YJ; Chen, Y; Ding, J; Geng, MY; Huang, M; Luo, HB; Miao, ZH; Qian, XH; Qin, YX; Shen, X; Xu, YF; Yang, F; Zhu, H | 1 |
| Alami, N; Belanger, S; Grieshaber, CK; Juste, S; Leyland-Jones, B; Paterson, J | 1 |
| Darro, F; Dewelle, J; Dumont, P; El Yazidi, M; Gaussin, JF; Kiss, R; Lefranc, F; Mahieu, T; Mijatovic, T; Ribaucour, F; Sauvage, S; Simon, G; Tuti, J; Van Quaquebeke, E; Van Vynckt, F | 1 |
| Ajami, AM; Capizzi, RL; Chau, M; Christensen, JL | 1 |
| Appella, DH; Avram, MJ; Ghosh, S; Huang, S; Kawamura, A; Luong, L; Norton, JT; Sim, E; Stack, MS; Witschi, MA | 1 |
| Cui, J; Liu, J; Qian, X; Wang, F; Xie, L; Xu, Y | 1 |
| Tallman, M | 1 |
| Liu, J; Qian, X; Wang, J; Wu, A; Xu, Y | 1 |
| Allen, SL; Bennett, JM; Budman, DR; Capizzi, RL; Kolitz, JE; Lundberg, AS | 1 |
| Cai, YJ; Ding, J; Feng, JM; Huang, M; Lu, JJ; Miao, ZH; Qian, XH; Tong, LJ; Xu, YF; Zhang, ZX; Zhu, H | 1 |
| Chen, Z; Kuang, D; Liang, X; Liu, J; Qian, X; Tan, S; Wang, X; Wang, Y; Xie, H; Xu, Y; Zhang, H; Zhu, W | 1 |
| Liang, X; Liu, J; Qian, X; Wu, A; Xu, K; Xu, Y | 1 |
| Cui, L; Qian, X; Xu, Y; Zhong, Y; Zhu, W | 1 |
| Liang, X; Liu, J; Qian, X; Xu, K; Xu, Y | 1 |
| Chen, Z; Lin, B; Liu, J; Qian, X; Xu, Y; Zhang, H | 1 |
| Appella, DH; Chen, Z; Huang, S; Liu, Y; Lou, G; Norton, JT; Wang, C; Witschi, MA; Xu, Q | 1 |
| Allen, SL; Lundberg, AS | 1 |
| Mei, P; Qian, X; Wu, A; Xu, Y | 1 |
| Feldman, EJ | 1 |
| Freeman, CL; Giles, FJ; Swords, R | 1 |
| Li, Y; Liu, J; Qian, X; Shao, J; Shen, K; Xu, Y | 1 |
| Li, Q; Li, Z; Wang, CJ; Xie, SQ; Zhang, YH; Zhao, J | 1 |
| Li, Q; Liu, J; Lu, Y; Ni, L; Qian, X; Shen, K; Sun, L; Xu, Y; Zhang, H | 1 |
| Allen, SL; Damon, L; Egyed, M; Erba, HP; Horst, HA; Jang, JH; Lundberg, AS; Masszi, T; Mazzola, E; Neuberg, D; Pigneux, A; Powell, B; Rizzieri, D; Sekeres, MA; Selleslag, D; Solomon, SR; Stone, RM; Stuart, RK; Tallman, MS; Venugopal, P; Warzocha, K; Wetzler, M | 1 |
| Chen, J; Kim, DH; Larson, AC; Omary, RA | 1 |
| Andrei, G; Kokosza, K; Piotrowska, DG; Schols, D; Snoeck, R | 1 |
| Li, M; Wang, C; Wang, Y; Xie, S; Zhang, J | 1 |
| Andrei, G; Grzonkowski, P; Gulej, R; Głowacka, IE; Piotrowska, DG; Schols, D; Snoeck, R | 1 |
| Barner-Kowollik, C; Lai, H; Lalevée, J; Lu, H; Lu, M; Stenzel, MH; Xiao, P; Zhao, J | 1 |
| Cao, ZR; Li, RF; Li, XL; Liu, X; Rong, RX; Wang, KR; Wang, SS | 1 |
| Kampert, TL; Misra, SK; Pan, D | 1 |
| Byczek-Wyrostek, A; Kasprzycki, P; Strama, K; Tomczyk, MD; Walczak, KZ; Wawszków, M | 1 |
| Bazylevich, A; Gellerman, G; Hershkovitz-Rokah, O; Patsenker, L; Shpilberg, O; Tuchinsky, H; Weissman, R; Zigman-Hoffman, E | 1 |
| Buhagiar, JA; Johnson, AD; Magri, DC; Valentino, M; Vella, J; Zammit, R | 1 |
| Fan, YR; Huang, Y; Jia, DG; Wang, BJ; Yang, XB | 1 |
| Cao, Y; Che, D; Dai, F; Fan, R; Feng, Y; Gao, L; Gao, M; Ge, C; Li, J; Wang, C; Wang, S; Wang, Y; Xie, S; Xu, X | 1 |
7 review(s) available for adenine and naphthalimides
| Article | Year |
|---|---|
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
New anticancer agents.
Topics: Adenine; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Depsipeptides; Echinomycin; Epirubicin; Flavonoids; Guanidines; Humans; Idarubicin; Imides; Isoquinolines; Menogaril; Naphthalimides; Nogalamycin; Organophosphonates; Pentostatin; Peptides, Cyclic; Polymers; Vidarabine Phosphate | 1988 |
New anticancer agents.
Topics: Adenine; Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Imides; Indoles; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pyridines; Topotecan; Vinblastine; Vinorelbine | 1994 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Topics: Adenine; Antineoplastic Agents; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Imides; Irinotecan; Isoquinolines; Mercaptopurine; Methyltransferases; Naphthalimides; Organophosphonates; Oxidoreductases; Pharmacogenetics; Phenotype | 2000 |
Amonafide: a potential role in treating acute myeloid leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Clinical Trials as Topic; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Survival Rate; Treatment Outcome | 2011 |
Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Naphthalimides; Organophosphonates; Topoisomerase II Inhibitors | 2012 |
40 trial(s) available for adenine and naphthalimides
| Article | Year |
|---|---|
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
Topics: Adenine; Adult; Aged; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organophosphonates; Ovarian Neoplasms | 1992 |
Phase II study of amonafide in advanced and recurrent sarcoma patients.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imides; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Naphthalimides; Organophosphonates; Recurrence; Sarcoma; Treatment Outcome | 1992 |
Evaluation of amonafide in cervical cancer, phase II. A SWOG study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Neoplasm Recurrence, Local; Organophosphonates; Survival Analysis; Uterine Cervical Neoplasms | 1992 |
Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Drug Resistance; Female; Granulocytes; Humans; Imides; Isoquinolines; Leukopenia; Male; Middle Aged; Multiple Myeloma; Naphthalimides; Organophosphonates; Recurrence; Thrombocytopenia | 1991 |
Phase II study of amonafide in advanced pancreatic adenocarcinoma.
Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Organophosphonates; Pancreatic Neoplasms | 1991 |
Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Naphthalimides; Organophosphonates | 1991 |
Phase II study of amonafide in advanced breast cancer.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cardiomyopathies; Drug Evaluation; Female; Humans; Imides; Infusions, Intravenous; Isoquinolines; Leukopenia; Middle Aged; Naphthalimides; Nausea; Organophosphonates | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1991 |
Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Drug Evaluation; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Organophosphonates | 1991 |
Phase I clinical investigation of amonafide.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Evaluation; Female; Half-Life; Humans; Imides; Isoquinolines; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Naphthalimides; Organophosphonates; Prostatic Neoplasms | 1989 |
Phase II study of amonafide in patients with recurrent glioma.
Topics: Adenine; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Nervous System Diseases; Oligodendroglioma; Organophosphonates; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 1995 |
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Topics: Acetylation; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imides; Isoquinolines; Leukopenia; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged; Multivariate Analysis; Naphthalimides; Organophosphonates; Racial Groups; Regression Analysis; Serum Albumin; United States | 1995 |
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Female; Hematologic Diseases; Humans; Imides; Isoquinolines; Male; Naphthalimides; Organophosphonates; Stomach Neoplasms | 1994 |
Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Topics: Adenine; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Neoplasms, Hormone-Dependent; Organophosphonates; Prostatic Neoplasms; Remission Induction | 1994 |
Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Nausea; Organophosphonates; Sarcoma; Soft Tissue Neoplasms; Vomiting | 1994 |
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
Topics: Acetylation; Adenine; Aging; Female; Humans; Imides; Isoquinolines; Leukocyte Count; Leukopenia; Male; Models, Statistical; Naphthalimides; Organophosphonates; Regression Analysis; Selection Bias; Sex Factors | 1994 |
A Gynecologic Oncology Group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Organophosphonates; Pelvic Neoplasms; Treatment Outcome; Uterine Cervical Neoplasms | 1994 |
Advanced colorectal adenocarcinoma: treatment with amonafide.
Topics: Adenine; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Organophosphonates | 1994 |
Amonafide as first-line chemotherapy for metastatic breast cancer.
Topics: Adenine; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Nausea; Neoplasm Metastasis; Organophosphonates; Treatment Outcome; Vomiting | 1994 |
A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Organophosphonates; Ovarian Neoplasms | 1993 |
Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Imides; Intercalating Agents; Isoquinolines; Middle Aged; Naphthalimides; Neoplasm Recurrence, Local; Organophosphonates; Survival Analysis; Treatment Outcome | 1994 |
Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study.
Topics: Adenine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drugs, Investigational; Esophageal Neoplasms; Female; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Organophosphonates; Prognosis | 1993 |
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Imides; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Naphthalimides; Neoplasm Staging; Organophosphonates; Trimetrexate | 1993 |
Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
Topics: Adenine; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Organophosphonates | 1993 |
Phase I study of amonafide dosing based on acetylator phenotype.
Topics: Acetylation; Adenine; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Imides; Intercalating Agents; Isoquinolines; Lymphoma; Male; Middle Aged; Models, Biological; Naphthalimides; Neoplasms; Organophosphonates; Phenotype | 1993 |
Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drugs, Investigational; Female; Gallium; Humans; Imides; Infusions, Intravenous; Isoquinolines; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Naphthalimides; Organophosphonates; Survival Rate; Teniposide | 1995 |
Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Imides; Isoquinolines; Male; Mathematics; Metabolic Clearance Rate; Middle Aged; Models, Biological; Naphthalimides; Neoplasms; Organophosphonates; Polymorphism, Genetic | 1996 |
Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study.
Topics: Adenine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Organophosphonates; Treatment Outcome | 1995 |
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imides; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Naphthalimides; Organophosphonates; Survival Rate; Treatment Outcome | 1996 |
An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Organophosphonates | 1997 |
A phase II trial of amonafide in patients with nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Topics: Adenine; Adult; Antineoplastic Agents; Carcinoma; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Organophosphonates; Uterine Cervical Neoplasms | 1997 |
Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Female; Humans; Imides; Isoquinolines; Leiomyosarcoma; Middle Aged; Naphthalimides; Organophosphonates; Uterine Neoplasms | 1998 |
A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imides; Isoquinolines; Leukopenia; Middle Aged; Mixed Tumor, Mesodermal; Naphthalimides; Organophosphonates; Thrombocytopenia; Uterine Neoplasms | 1998 |
A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Organophosphonates | 1998 |
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Imides; Isoquinolines; Menopause; Middle Aged; Naphthalimides; Neoplasm Metastasis; Organophosphonates; Receptors, Estrogen | 1995 |
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Topics: Adenine; Adult; Aged; Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Imides; Isoquinolines; Melphalan; Middle Aged; Naphthalimides; Neoplasm Staging; Organophosphonates; Prospective Studies; Survival Analysis; Trimetrexate | 1999 |
Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
Topics: Adenine; Adult; Antineoplastic Agents; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Humans; Imides; Infusions, Intravenous; Isoquinolines; Male; Naphthalimides; Organophosphonates | 2002 |
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Remission Induction; Risk Factors; Treatment Outcome; Young Adult | 2010 |
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2015 |
68 other study(ies) available for adenine and naphthalimides
| Article | Year |
|---|---|
Studies about the oral bioavailability of mitonafide and 2HCl amonafide, two new cytotoxic molecules.
Topics: Adenine; Antineoplastic Agents; Biological Availability; Hydrogen-Ion Concentration; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Organophosphonates; Solubility | 1992 |
Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
Topics: Adenine; Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Drug Tolerance; Female; Humans; Imides; Intercalating Agents; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Naphthalimides; Neoplasm Staging; Organophosphonates; Remission Induction | 1991 |
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Topics: Acetylation; Adenine; Antineoplastic Agents; Body Weight; Female; Humans; Imides; Isoquinolines; Leukopenia; Male; Middle Aged; Naphthalimides; Organophosphonates; Phenotype; Prospective Studies | 1991 |
Amonafide in metastatic colorectal carcinoma.
Topics: Adenine; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Neoplasm Metastasis; Organophosphonates | 1990 |
Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.
Topics: Adenine; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Protocols; Drug Evaluation; Drugs, Investigational; Female; Humans; Imides; Infusions, Intravenous; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Naphthalimides; Organophosphonates | 1990 |
Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Topics: Adenine; Animals; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Viral; Haplorhini; Imides; In Vitro Techniques; Intercalating Agents; Isoquinolines; Naphthalimides; Nucleic Acid Conformation; Organophosphonates; Simian virus 40; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1989 |
Correspondence re: Mark J. Ratain et al., Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics.
Topics: Adenine; Antineoplastic Agents; Circadian Rhythm; Humans; Imides; Isoquinolines; Naphthalimides; Organophosphonates | 1989 |
Genotoxicity of [1H]benz[de]isoquinoline-1,3[2H]dione,5 amino-2-,[2-dimethylamino) ethyl] (BIDA) in human lymphocytes.
Topics: Adenine; Adult; Antineoplastic Agents; Cells, Cultured; Chromosome Aberrations; Humans; Imides; Interphase; Isoquinolines; Lymphocyte Activation; Lymphocytes; Male; Mutagens; Naphthalimides; Organophosphonates; Phytohemagglutinins; Sister Chromatid Exchange | 1989 |
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia.
Topics: Adenine; Amsacrine; Cell Line; Clone Cells; DNA; DNA Topoisomerases, Type I; Doxorubicin; Electrophoresis, Agar Gel; Humans; Imides; In Vitro Techniques; Intercalating Agents; Isoquinolines; Leukemia, Myeloid, Acute; Mathematics; Naphthalimides; Organophosphonates | 1987 |
In vitro activity of amonafide against primary human tumors compared with the activity of standard agents.
Topics: Adenine; Antineoplastic Agents; Drug Evaluation; Drug Evaluation, Preclinical; Hematopoietic Stem Cells; Humans; Imides; Isoquinolines; Naphthalimides; Organophosphonates; Tumor Cells, Cultured | 1988 |
Pharmacokinetics of Amonafide in dogs.
Topics: Adenine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Dogs; Female; Fluorometry; Gas Chromatography-Mass Spectrometry; Imides; Infusions, Intravenous; Isoquinolines; Male; Naphthalimides; Organophosphonates; Oxidation-Reduction; Regression Analysis; Software; Tissue Distribution | 1988 |
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
Topics: Adenine; Drug Evaluation; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Organophosphonates | 1988 |
Phase I clinical investigation of benzisoquinolinedione.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hematopoiesis; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Organophosphonates | 1987 |
Sensitive reversed-phase high-performance liquid chromatographic assay for the antitumor agent benzisoquinolinedione (Nafidimide) employing direct on-column injection of plasma and urine, and its use for pharmacokinetic studies in a dog.
Topics: Adenine; Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dogs; Female; Half-Life; Imides; Injections, Intravenous; Isoquinolines; Kinetics; Naphthalimides; Organophosphonates | 1985 |
High-performance liquid chromatographic separation and quantitation of benzisoquinolinedione (Nafidimide) from biological fluids.
Topics: Adenine; Animals; Antineoplastic Agents; Bile; Body Fluids; Chromatography, High Pressure Liquid; Dogs; Imides; Isoquinolines; Kinetics; Naphthalimides; Organophosphonates | 1985 |
Antiviral action of 5-amino-2-(2-dimethyl-aminoethyl)benzo-[de]-isoquinolin-1,3-dion e.
Topics: Adenine; African Swine Fever Virus; Animals; Antiviral Agents; Cell Line; Cell Survival; Chick Embryo; Chlorocebus aethiops; DNA Replication; Drug Evaluation, Preclinical; Imides; Iridoviridae; Isoquinolines; Kidney; Kinetics; Naphthalimides; Organophosphonates; Simplexvirus; Virus Replication | 1984 |
Imide derivatives of 3-nitro-1.8-naphthalic acid: their inhibitory activity against DNA viruses.
Topics: Adenine; Adenoviruses, Human; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Chick Embryo; Chlorocebus aethiops; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Imides; Isoquinolines; Naphthalimides; Organophosphonates; Simplexvirus; Time Factors; Virus Replication | 1982 |
[Antineoplastic drugs used as fluorochromes].
Topics: Adenine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Chickens; DNA; Fluorescent Dyes; Imides; Isoquinolines; Naphthalimides; Organophosphonates | 1982 |
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
Topics: Adenine; Animals; Antineoplastic Agents; Cattle; Colonic Neoplasms; DNA; Doxorubicin; Heart Diseases; Humans; Imides; Isoquinolines; Leukemia P388; Male; Mice; Mice, Inbred DBA; Mitoxantrone; Naphthalimides; Organophosphonates; Structure-Activity Relationship; Tumor Cells, Cultured | 1995 |
Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.
Topics: Adenine; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; DNA; DNA Topoisomerases, Type II; DNA, Viral; Imides; Isoquinolines; Leukemia P388; Mice; Molecular Sequence Data; Naphthalimides; Organophosphonates; Sequence Analysis, DNA; Simian virus 40 | 1995 |
Qualitative and quantitative determination of two new antitumor agents from 1-8 naphthalimides in tablets. Validation of a high performance liquid chromatography method.
Topics: Adenine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Excipients; Imides; Isoquinolines; Naphthalimides; Organophosphonates; Regression Analysis; Tablets | 1994 |
Bis-naphthalimides: a new class of antitumor agents.
Topics: Adenine; Animals; Antineoplastic Agents; Humans; Imides; Intercalating Agents; Isoquinolines; Mice; Naphthalenes; Naphthalimides; Neoplasms, Experimental; Organophosphonates; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
The correlation of response with plasma pharmacokinetics and polyamine concentrations in patients with acute myelogenous leukemia receiving amonafide.
Topics: Adenine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Half-Life; Humans; Imides; Isoquinolines; Leukemia, Myeloid, Acute; Leukocyte Count; Metabolic Clearance Rate; Naphthalimides; Organophosphonates; Polyamines; Regression Analysis; Time Factors | 1993 |
Synthesis, structure and antitumor activity of new benz[d,e]isoquinoline-1,3-diones.
Topics: Adenine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Imides; Isoquinolines; Leukemia L1210; Mice; Mice, Inbred DBA; Models, Molecular; Molecular Conformation; Naphthalimides; Organophosphonates; Tumor Cells, Cultured | 1995 |
Computer simulation of the binding of amonafide and azonafide to DNA.
Topics: Adenine; Base Sequence; Binding Sites; Calorimetry; Computer Simulation; DNA; Hydrogen Bonding; Imides; Intercalating Agents; Isoquinolines; Molecular Conformation; Molecular Sequence Data; Molecular Structure; Naphthalimides; Nucleic Acid Conformation; Oligodeoxyribonucleotides; Organophosphonates | 1996 |
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Topics: Acetylation; Adenine; Adult; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Imides; Isoquinolines; Leukocyte Count; Leukopenia; Male; Middle Aged; Models, Biological; Naphthalimides; Organophosphonates; Phenotype; Prospective Studies; Sex Factors | 1996 |
The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
Topics: Adenine; Alleles; Antineoplastic Agents; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Humans; Imides; Isoquinolines; Mesylates; Naphthalimides; Organophosphonates; Saccharomyces cerevisiae | 1998 |
Analogues of amonafide and azonafide with novel ring systems.
Topics: Adenine; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Imides; Isoquinolines; Mice; Naphthalimides; Organophosphonates; Phenanthrenes; Structure-Activity Relationship; Tumor Cells, Cultured | 2000 |
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Topics: Adenine; Antineoplastic Agents; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pharmacogenetics; Polymorphism, Genetic | 2001 |
Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators.
Topics: Adenine; Animals; Antineoplastic Agents; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Imides; Intercalating Agents; Isoquinolines; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Naphthalimides; Neoplasms; Organophosphonates; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.
Topics: Adenine; Amides; Animals; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; Furans; Humans; Imides; Intercalating Agents; Isoquinolines; Mice; Mice, Nude; Models, Molecular; Naphthalimides; Neoplasm Transplantation; Organophosphonates; Structure-Activity Relationship; Thiophenes; Transplantation, Heterologous | 2004 |
Statistical method for evaluation of dissolution stability in the formulation development of solid dosage forms: tablets of amonafide.
Topics: Adenine; Algorithms; Antineoplastic Agents; Chemistry, Pharmaceutical; Imides; Isoquinolines; Models, Statistical; Naphthalimides; Organophosphonates; Solubility; Spectrophotometry, Ultraviolet; Tablets | 2004 |
Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: effects of intercalation, side chains, and substituent groups.
Topics: Adenine; Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; DNA; DNA, Superhelical; Drug Screening Assays, Antitumor; Humans; Imides; Intercalating Agents; Isoquinolines; Leukemia P388; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mice; Models, Molecular; Naphthalenes; Naphthalimides; Organophosphonates; Phthalimides; Structure-Activity Relationship; Thiadiazines; Ultraviolet Rays | 2005 |
Influence of inter- and intramolecular hydrogen bonding on kemp decarboxylations from QM/MM simulations.
Topics: Adenine; Carboxylic Acids; Computer Simulation; Hydrogen Bonding; Imides; Isoquinolines; Models, Molecular; Monte Carlo Method; Naphthalimides; Organophosphonates; Quantum Theory; Solvents; Thermodynamics | 2005 |
Hole transfer in DNA and photosensitized DNA damage: importance of adenine oxidation.
Topics: Absorption; Adenine; Base Sequence; DNA; DNA Damage; Lasers; Light; Models, Chemical; Molecular Sequence Data; Naphthalimides; Nucleic Acid Conformation; Oxidation-Reduction; Oxygen; Photolysis; Photosensitizing Agents | 2007 |
R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cell Proliferation; Cytochromes c; DNA Topoisomerases, Type II; Enzyme Inhibitors; Female; Flow Cytometry; G2 Phase; Humans; Imides; In Situ Nick-End Labeling; Isoquinolines; Liver Neoplasms, Experimental; Mice; Mice, Inbred Strains; Naphthalimides; Organophosphonates; Poly(ADP-ribose) Polymerases; Sarcoma, Experimental; Thiophenes; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2007 |
Comparative analysis of xanafide cytotoxicity in breast cancer cell lines.
Topics: Adenine; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Imides; Isoquinolines; Mice; Mice, Nude; Naphthalimides; Organophosphonates | 2007 |
2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.
Topics: Acetamides; Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cellular Senescence; Deoxycytidine; Drug Screening Assays, Antitumor; Erythrocyte Count; Female; Gemcitabine; Humans; Imides; Irinotecan; Isoquinolines; Leukocyte Count; Maximum Tolerated Dose; Mice; Naphthalimides; Neoplasm Transplantation; Organophosphonates; Platelet Count; Structure-Activity Relationship; Topoisomerase I Inhibitors; Urea | 2007 |
Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.
Topics: Adenine; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Imides; Isoquinolines; Mice; Naphthalimides; Organophosphonates; Topoisomerase II Inhibitors | 2008 |
Synthesis and anticancer activities of 6-amino amonafide derivatives.
Topics: Acetylation; Adenine; Animals; Antineoplastic Agents; Arylamine N-Acetyltransferase; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; DNA; DNA Damage; Humans; Imides; Intercalating Agents; Isoquinolines; Magnetic Resonance Spectroscopy; Naphthalimides; Neoplasm Invasiveness; Organophosphonates; Structure-Activity Relationship; Subcellular Fractions; Topoisomerase I Inhibitors | 2008 |
Mechanism of charge separation in DNA by hole transfer through consecutive adenines.
Topics: Adenine; Bromouracil; DNA; Kinetics; Molecular Structure; Naphthalimides; Photolysis; Photosensitizing Agents; Quantum Theory; Time Factors | 2008 |
Synthesis of new amonafide analogues via coupling reaction and their cytotoxic evaluation and DNA-binding studies.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Humans; Naphthalenes; Naphthalimides; Organophosphonates; Structure-Activity Relationship | 2009 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
M(2)-A induces apoptosis and G(2)-M arrest via inhibiting PI3K/Akt pathway in HL60 cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; DNA Fragmentation; Flow Cytometry; G2 Phase; HL-60 Cells; Humans; Microscopy, Fluorescence; Naphthalimides; Organophosphonates; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2009 |
Naphthalimides induce G(2) arrest through the ATM-activated Chk2-executed pathway in HCT116 cells.
Topics: Adenine; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Cell Cycle Proteins; Checkpoint Kinase 2; DNA Breaks, Double-Stranded; DNA-Binding Proteins; Flow Cytometry; Fluorescent Antibody Technique; G2 Phase; HCT116 Cells; Humans; Naphthalimides; Organophosphonates; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; Thiophenes; Transfection; Tumor Suppressor Proteins | 2009 |
A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Binding, Competitive; Cell Line, Tumor; Cell Survival; Circular Dichroism; DNA; DNA Topoisomerases, Type II; Drug Design; HeLa Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Membranes; Lysosomes; Models, Chemical; Molecular Structure; Naphthalimides; Organophosphonates; Permeability; Plasmids; Spectrometry, Fluorescence; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2010 |
B1, a novel naphthalimide-based DNA intercalator, induces cell cycle arrest and apoptosis in HeLa cells via p53 activation.
Topics: Adenine; Apoptosis; Benzothiazoles; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cell Shape; Cell Survival; Cytochromes c; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Fluorescence; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Intercalating Agents; Mitochondria; Naphthalimides; Necrosis; Organophosphonates; RNA, Messenger; RNA, Small Interfering; Staining and Labeling; Time Factors; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2011 |
Selective and sensitive detection and quantification of arylamine N-acetyltransferase 2 by a ratiometric fluorescence probe.
Topics: Acetylation; Adenine; Arylamine N-Acetyltransferase; Fluorescent Dyes; Hep G2 Cells; Humans; Microscopy, Fluorescence; Naphthalimides; Organophosphonates; Sensitivity and Specificity; Spectrometry, Fluorescence | 2010 |
B1, a novel amonafide analogue, overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells.
Topics: 14-3-3 Proteins; Adenine; Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, bcl-2; Genes, MDR; Genes, p53; HL-60 Cells; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Naphthalimides; Organophosphonates; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; U937 Cells | 2010 |
7-b, a novel amonafide analogue, cause growth inhibition and apoptosis in Raji cells via a ROS-mediated mitochondrial pathway.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Burkitt Lymphoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Humans; Mitochondria; Models, Biological; Naphthalimides; Necrosis; Organophosphonates; Reactive Oxygen Species; Signal Transduction | 2011 |
Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line; Disease Models, Animal; Gene Expression Profiling; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Naphthalimides; Organophosphonates; Stomach Neoplasms; Transplantation, Heterologous | 2011 |
Novel naphthalimide-benzoic acid conjugates as potential apoptosis-inducing agents: design, synthesis, and biological activity.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Benzoic Acid; Cell Line, Tumor; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Naphthalimides; Organophosphonates; Structure-Activity Relationship | 2011 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles | 2011 |
E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Caffeine; Cell Cycle Proteins; Comet Assay; Cyclin-Dependent Kinase Inhibitor p21; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; E2F1 Transcription Factor; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Gene Knockout Techniques; HCT116 Cells; HeLa Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; K562 Cells; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Naphthalimides; Organophosphonates; Protein Serine-Threonine Kinases; Rats; Signal Transduction; Time Factors; Tumor Suppressor Protein p53 | 2012 |
BND-12, a novel nonhaematotoxic naphthalimide derivative, inhibits tumour growth and metastasis of hepatocellular carcinoma.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Male; Mice; Mitochondria; Naphthalimides; Neoplasm Metastasis; Organophosphonates; Survival Rate; Toxicity Tests; Xenograft Model Antitumor Assays | 2012 |
A ROS-mediated lysosomal-mitochondrial pathway is induced by a novel Amonafide analogue, 7c, in human Hela cervix carcinoma cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; HeLa Cells; Humans; Intracellular Membranes; Lysosomes; Membrane Potential, Mitochondrial; Mitochondria; Naphthalimides; Organophosphonates; Permeability; Reactive Oxygen Species | 2013 |
MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors.
Topics: Adenine; Alginates; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Glucuronic Acid; Hexuronic Acids; Injections, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Microspheres; Naphthalimides; Organophosphonates; Rats | 2015 |
Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
Topics: Acrylamides; Adenine; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Cell Survival; Cycloaddition Reaction; Cytomegalovirus; Cytostatic Agents; Drug Design; Enterovirus; Humans; Isoxazoles; Naphthalimides; Nitrogen Oxides; Organophosphonates; Phlebovirus; Simplexvirus; Structure-Activity Relationship; Vaccinia virus | 2015 |
Synthesis and evaluation of novel amonafide-polyamine conjugates as anticancer agents.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microscopy, Fluorescence; Naphthalimides; Neoplasms; Organophosphonates; Polyamines; Transplantation, Heterologous | 2017 |
Synthesis and the Biological Activity of Phosphonylated 1,2,3-Triazolenaphthalimide Conjugates.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Proliferation; Cytostatic Agents; HeLa Cells; Herpesvirus 3, Human; Humans; Inhibitory Concentration 50; Molecular Structure; Naphthalimides; Organophosphonates | 2016 |
Delivery of Amonafide from Fructose-Coated Nanodiamonds by Oxime Ligation for the Treatment of Human Breast Cancer.
Topics: Adenine; Breast Neoplasms; Coated Materials, Biocompatible; Drug Delivery Systems; Female; Fructose; Humans; MCF-7 Cells; Nanodiamonds; Naphthalimides; Organophosphonates | 2018 |
Lysosomes-targeting imaging and anticancer properties of novel bis-naphthalimide derivatives.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; Fluorescence; Fluorescent Dyes; Humans; Lysosomes; Microscopy, Confocal; Microscopy, Fluorescence; Naphthalimides; Nucleic Acid Conformation; Organophosphonates; Piperazines; Piperidines; S Phase Cell Cycle Checkpoints; Transition Temperature; Zebrafish | 2018 |
Nano-Assembly of Pamitoyl-Bioconjugated Coenzyme-A for Combinatorial Chemo-Biologics in Transcriptional Therapy.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Coenzyme A; Drug Carriers; Humans; Melanoma; Nanoparticles; Naphthalimides; Organophosphonates; Protein Multimerization; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; RNAi Therapeutics | 2018 |
Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Naphthalimides; Organophosphonates; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2019 |
Synthesis and Biological Studies of New Multifunctional Curcumin Platforms for Anticancer Drug Delivery.
Topics: Adenine; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Chlorambucil; Curcumin; Drug Carriers; Drug Liberation; Humans; Naphthalimides; Organophosphonates; Phosphorylation; Prodrugs; Transcription Factor RelA | 2019 |
Aminonaphthalimide hybrids of mitoxantrone and amonafide as anticancer and fluorescent cellular imaging agents.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Fluorescent Dyes; Humans; Microscopy, Fluorescence; Mitoxantrone; Naphthalimides; Organophosphonates; Phthalimides; Spectrometry, Fluorescence | 2019 |
Synthesis, electrochemistry, DNA binding and in vitro cytotoxic activity of tripodal ferrocenyl bis-naphthalimide derivatives.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; Electrochemistry; Ethidium; Ferrous Compounds; Flow Cytometry; Humans; Metallocenes; Molecular Structure; Naphthalimides; Organophosphonates; Reactive Oxygen Species; Structure-Activity Relationship | 2021 |
Reactive Oxygen Species Mediate 6c-Induced Mitochondrial and Lysosomal Dysfunction, Autophagic Cell Death, and DNA Damage in Hepatocellular Carcinoma.
Topics: Acetylcysteine; Adenine; Antioxidants; Autophagic Cell Death; Autophagosomes; Carcinoma, Hepatocellular; DNA Damage; Hep G2 Cells; Humans; Liver Neoplasms; Lysosomes; Microtubule-Associated Proteins; Mitochondria; Naphthalimides; Proteome; Proteomics; Reactive Oxygen Species; Sequestosome-1 Protein | 2021 |